title: Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation.
abstract: OBJECTIVE
  Little is known about the influence of calcineurin inhibitors on advanced oxidation protein products (AOPP) and total antioxidant status (TAS) after renal transplantation.
  
  
  METHODS
  AOPP and TAS were evaluated in transplanted patients on different calcineurin inhibitors. Thirty-five patients were treated with cyclosporine A (group A) and 33 with tacrolimus (group B).
  
  
  RESULTS
  Over 6 months, the mean levels of AOPP in group A decreased from 205.9+/-125.7 to 140.9+/-78.9 micromol/L and TAS from 1.89+/-0.30 to 1.75+/-0.27 mmol/L. In group B, the mean levels of AOPP decreased from 196.5+/-123.9 to 129.6+/-63.8 micromol/L and TAS from 1.80+/-0.39 to 1.78+/-0.23 mmol/L.
  
  
  CONCLUSIONS
  No significant differences in AOPP and TAS were found with respect to treatment. The only exception was the higher mean concentration of AOPP at month 1 in group A (p=0.026).
authors.affiliation: Department of Internal Medicine III, University Hospital, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic. josef.zadrazil@fnol.cz
authors.forename: Josef
authors.initials: J
authors.lastname: Zadrazil
authors.forename: Pavel
authors.initials: P
authors.lastname: Strebl
authors.forename: Karel
authors.initials: K
authors.lastname: Krejcí
authors.forename: Vladko
authors.initials: V
authors.lastname: Horcicka
authors.forename: Pavel
authors.initials: P
authors.lastname: Horák
authors.forename: Jitka
authors.initials: J
authors.lastname: Vostálová
authors.forename: Adéla
authors.initials: A
authors.lastname: Zdarilová
authors.forename: Markéta
authors.initials: M
authors.lastname: Kajabová
authors.forename: Petr
authors.initials: P
authors.lastname: Schneiderka
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000378:metabolism*; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000534:rehabilitation / Q000628:therapy; D016030:Kidney Transplantation / Q000534:rehabilitation; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D011506:Proteins / Q000378:metabolism*; D016559:Tacrolimus / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D011506:Proteins; D016572:Cyclosporine; D016559:Tacrolimus